Judith A. Aberg

22.8k total citations · 5 hit papers
200 papers, 9.2k citations indexed

About

Judith A. Aberg is a scholar working on Infectious Diseases, Emergency Medicine and Epidemiology. According to data from OpenAlex, Judith A. Aberg has authored 200 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Infectious Diseases, 79 papers in Emergency Medicine and 59 papers in Epidemiology. Recurrent topics in Judith A. Aberg's work include HIV-related health complications and treatments (79 papers), HIV/AIDS drug development and treatment (64 papers) and HIV Research and Treatment (55 papers). Judith A. Aberg is often cited by papers focused on HIV-related health complications and treatments (79 papers), HIV/AIDS drug development and treatment (64 papers) and HIV Research and Treatment (55 papers). Judith A. Aberg collaborates with scholars based in United States, Spain and United Kingdom. Judith A. Aberg's co-authors include Joel E. Gallant, Judith S. Currier, Carl J. Fichtenbaum, Patricia Emmanuel, Michael A. Horberg, William G. Powderly, John G. Gerber, Marshall J. Glesby, Khalil G. Ghanem and Barry S. Zingman and has published in prestigious journals such as Science, New England Journal of Medicine and JAMA.

In The Last Decade

Judith A. Aberg

186 papers receiving 8.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

2020 648 citations Ania Wajnberg, Fatima Amanat et al. Science profile →
Antiretroviral Treatment of Adult HIV Infection

2010 595 citations Judith A. Aberg et al. profile →
Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America

2013 363 citations Judith A. Aberg et al. Clinical Infectious Diseases profile →
Antiretroviral Treatment of Adult HIV Infection

2014 352 citations Judith A. Aberg, Marshall J. Glesby et al. profile →
The Science and Value of Diversity: Closing the Gaps in Our Understanding of Inclusion and Diversity

2019 171 citations Talia H. Swartz, Ann‐Gel S. Palermo et al. The Journal of Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Judith A. Aberg United States	51	5.9k	3.0k	2.9k	2.5k	982	200	9.2k
Alexandra Calmy Switzerland	53	6.5k 1.1×	3.2k 1.1×	3.3k 1.2×	3.8k 1.5×	588 0.6×	305	10.1k
Giovanni Guaraldi Italy	46	4.0k 0.7×	3.1k 1.0×	4.1k 1.4×	1.9k 0.7×	666 0.7×	407	9.4k
Jennifer Hoy Australia	47	5.3k 0.9×	2.9k 0.9×	2.8k 1.0×	3.2k 1.3×	457 0.5×	242	8.3k
Colette Smith United Kingdom	40	3.7k 0.6×	2.8k 0.9×	1.6k 0.6×	1.6k 0.6×	569 0.6×	233	6.9k
Estebán Martínez Spain	47	5.0k 0.8×	2.4k 0.8×	3.6k 1.3×	3.1k 1.2×	538 0.5×	323	8.5k
Enos Bernasconi Switzerland	56	7.2k 1.2×	4.0k 1.3×	3.0k 1.0×	4.1k 1.6×	508 0.5×	303	10.5k
Anton Pozniak United Kingdom	53	8.2k 1.4×	3.5k 1.2×	1.9k 0.6×	5.2k 2.1×	719 0.7×	294	10.7k
Sharon Walmsley Canada	47	6.6k 1.1×	4.0k 1.3×	1.9k 0.7×	4.2k 1.7×	444 0.5×	331	10.8k
Judith S. Currier United States	51	7.3k 1.2×	2.9k 1.0×	5.8k 2.0×	5.0k 2.0×	1.2k 1.2×	294	12.2k
Matthew Bidwell Goetz United States	51	3.8k 0.6×	4.2k 1.4×	2.4k 0.8×	1.5k 0.6×	739 0.8×	274	9.2k

Countries citing papers authored by Judith A. Aberg

Since Specialization

Citations

This map shows the geographic impact of Judith A. Aberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith A. Aberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith A. Aberg more than expected).

Fields of papers citing papers by Judith A. Aberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith A. Aberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith A. Aberg. The network helps show where Judith A. Aberg may publish in the future.

Co-authorship network of co-authors of Judith A. Aberg

This figure shows the co-authorship network connecting the top 25 collaborators of Judith A. Aberg. A scholar is included among the top collaborators of Judith A. Aberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith A. Aberg. Judith A. Aberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paules, Catharine I., Kathryn Shaw‐Saliba, Judith A. Aberg, et al.. (2025). Blood absolute lymphocyte count and trajectory are important in understanding severe COVID-19. BMC Infectious Diseases. 25(1). 67–67. 2 indexed citations

Kolossváry, Márton, Irini Sereti, Markella V. Zanni, et al.. (2025). Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV. Journal of Clinical Investigation. 135(22).

Grinspoon, Steven, Estebán Martínez, Carl J. Fichtenbaum, et al.. (2025). Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2. Clinical Infectious Diseases. 82(2). e248–e257.

Smith, Emma, Carlos Malvestutto, Heather J. Ribaudo, et al.. (2025). Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort. Open Forum Infectious Diseases. 12(4). ofaf177–ofaf177.

deFilippi, Christopher R., Sara McCallum, Markella V. Zanni, et al.. (2024). Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV. SHILAP Revista de lepidopterología. 3(9). 101206–101206. 3 indexed citations

Erlandson, Kristine M., Triin Umbleja, Heather J. Ribaudo, et al.. (2024). Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function. Clinical Infectious Diseases. 80(2). 425–433. 1 indexed citations

Swartz, Talia H. & Judith A. Aberg. (2023). Preserving the Future of Infectious Diseases: Why We Must Address the Decline in Compensation for Clinicians and Researchers. Clinical Infectious Diseases. 77(10). 1387–1394. 12 indexed citations

Kolossváry, Márton, Christopher R. deFilippi, Sara McCallum, et al.. (2023). Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV. EBioMedicine. 90. 104538–104538. 2 indexed citations

Kolossváry, Márton, Christopher R. deFilippi, Michael T. Lu, et al.. (2022). Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. The Journal of Infectious Diseases. 226(10). 1809–1822. 9 indexed citations

10.

Lo, Janet, Carlos Malvestutto, Kathleen V. Fitch, et al.. (2021). Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infectious Diseases. 8(12). ofab537–ofab537. 27 indexed citations

11.

Ventuneac, Ana, et al.. (2020). A mobile health intervention in HIV primary care: supporting patients at risk for ART non-adherence. SHILAP Revista de lepidopterología. 21(5). 140–150. 7 indexed citations

12.

Wajnberg, Ania, Fatima Amanat, Adolfo Firpo, et al.. (2020). Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 370(6521). 1227–1230. 648 indexed citations breakdown →

13.

Ho, Hung‐Yao, Marco Peluso, João Pedro Lopes, et al.. (2020). Immunologic characteristics of acute COVID-19 in people with HIV. Journal of the International AIDS Society. 23. 172–173.

14.

Swartz, Talia H., Ann‐Gel S. Palermo, Sandra K. Masur, & Judith A. Aberg. (2019). The Science and Value of Diversity: Closing the Gaps in Our Understanding of Inclusion and Diversity. The Journal of Infectious Diseases. 220(Supplement_2). S33–S41. 171 indexed citations breakdown →

15.

O’Brien, Meagan P., M. Urooj Zafar, José Carlos del Castillo Rodríguez, et al.. (2019). Targeting thrombogenicity and inflammation in chronic HIV infection. Science Advances. 5(6). eaav5463–eaav5463. 22 indexed citations

16.

Raifman, Julia, Keri N. Althoff, Peter F. Rebeiro, et al.. (2018). Human Immunodeficiency Virus (HIV) Viral Suppression After Transition From Having No Healthcare Coverage and Relying on Ryan White HIV/AIDS Program Support to Medicaid or Private Health Insurance. Clinical Infectious Diseases. 69(3). 538–541. 9 indexed citations

17.

Agwu, Allison L., John A. Fleishman, Bareng A. S. Nonyane, et al.. (2017). Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: Results from the HIVRN Cohort. PLoS ONE. 12(2). e0171125–e0171125. 2 indexed citations

18.

Gaisa, Michael, et al.. (2016). High Rates of Anal High-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Who Do Not Meet Screening Guidelines. Clinical Infectious Diseases. 64(3). 289–294. 27 indexed citations

19.

Aberg, Judith A.. (2013). Aging, inflammation, and HIV infection.. PubMed. 20(3). 101–5. 107 indexed citations

20.

Glesby, Marshall J., Judith A. Aberg, Michelle A. Kendall, et al.. (2005). Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clinical Pharmacology & Therapeutics. 78(2). 143–153. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact